Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago.

Dermatol Ther (Heidelb) · 2022 · PMC8941069 · PMID 35226302

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Taking ustekinumab as the reference drug, we observed that patients being treated with efalizumab (HR 7.94, 95% CI 3.42–18.44; p < 0.001) and infliximab (HR 2.79, 95% CI 1.01–7.72; p = 0.048) showed a trend of significantly higher HR of switching.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.